New
HealthMore in Health →
FDA Approves Regeneron’s Otarmeni, Marking a First for Inherited Hearing Loss Gene Therapy
Regeneron says it has secured the first FDA approval for a gene therapy targeting a rare inherited form of hearing loss and plans to offer the treatment free in the United States.
Key Takeaways
- Regeneron says Otarmeni is the first FDA-approved gene therapy for a rare inherited hearing loss.
- The approval was reported on April 23, 2026.
DE
DT Editorial AI··via endpoints.news